Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 11:00PM GMT
Release Date Price: €18.9 (-9.13%)
Alec Warren Stranahan
BofA Securities, Research Division - Associate

Good afternoon, and welcome to the end of day 1 of the 2022 Bank of America Healthcare Conference. Thanks for joining this session with REGENXBIO. My name is Alec Stranahan, I'm Vice President and Senior Biotech Analyst covering REGENX here at BofA. And I'm pleased to be joined today by Ken Mills, President and CEO of REGENX as well as Steve. Thank you guys for joining. I really appreciate it. And I believe that Ken is going to run through some of the initial comments, and then we'll go into the Q&A.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Sounds great. Thanks out to you and the entire team for hosting. It's great to be back in-person and good to have some discourse with people. I had a lot of great meetings, so it's good to have a little bit of time up on stage. Transformative year and last year for REGENXBIO as a company. We had a lot of growth in people, in our plan, in our science and come into 2022 in a really strong capital position.

We had -- one

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot